DK1667523T3 - DNA-vaccinesammensætninger og fremgangsmåder til deres anvendelse - Google Patents

DNA-vaccinesammensætninger og fremgangsmåder til deres anvendelse

Info

Publication number
DK1667523T3
DK1667523T3 DK04784389.1T DK04784389T DK1667523T3 DK 1667523 T3 DK1667523 T3 DK 1667523T3 DK 04784389 T DK04784389 T DK 04784389T DK 1667523 T3 DK1667523 T3 DK 1667523T3
Authority
DK
Denmark
Prior art keywords
methods
vaccine compositions
dna vaccine
dna
compositions
Prior art date
Application number
DK04784389.1T
Other languages
Danish (da)
English (en)
Inventor
Opendra Narayan
Zhenqian Liu
Original Assignee
Univ Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center filed Critical Univ Kansas Medical Center
Application granted granted Critical
Publication of DK1667523T3 publication Critical patent/DK1667523T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04784389.1T 2003-09-16 2004-09-16 DNA-vaccinesammensætninger og fremgangsmåder til deres anvendelse DK1667523T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50319703P 2003-09-16 2003-09-16
US10/941,164 US7488485B2 (en) 2003-09-16 2004-09-15 DNA vaccine compositions and methods of use
PCT/US2004/030512 WO2005027844A2 (en) 2003-09-16 2004-09-16 Dna vaccine compositions and methods of use

Publications (1)

Publication Number Publication Date
DK1667523T3 true DK1667523T3 (da) 2013-01-21

Family

ID=34381064

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04784389.1T DK1667523T3 (da) 2003-09-16 2004-09-16 DNA-vaccinesammensætninger og fremgangsmåder til deres anvendelse

Country Status (13)

Country Link
US (3) US7488485B2 (enExample)
EP (1) EP1667523B1 (enExample)
JP (1) JP4989224B2 (enExample)
AU (1) AU2004273965B2 (enExample)
BR (1) BRPI0414442A (enExample)
CA (1) CA2538840C (enExample)
DK (1) DK1667523T3 (enExample)
ES (1) ES2399875T3 (enExample)
IL (1) IL174325A (enExample)
NZ (1) NZ545954A (enExample)
PL (1) PL1667523T3 (enExample)
PT (1) PT1667523E (enExample)
WO (1) WO2005027844A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US8765140B2 (en) * 2003-09-16 2014-07-01 University Of Kansas Medical Center DNA vaccine compositions with HIV/SIV gene modifications
PT1880008E (pt) * 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
US7585675B2 (en) * 2005-11-15 2009-09-08 University Of Kansas Medical Center Inhibition of HIV and SHIV replication with antisense interleukin-4
FR2979919B1 (fr) * 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
WO2013126469A1 (en) * 2012-02-21 2013-08-29 Immunogenetix Therapeutics, Inc. Chimeric dna vaccine compositions and methods of use
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses

Also Published As

Publication number Publication date
EP1667523B1 (en) 2012-11-21
US8916174B2 (en) 2014-12-23
US20090233857A1 (en) 2009-09-17
AU2004273965A1 (en) 2005-03-31
PT1667523E (pt) 2013-02-04
AU2004273965B2 (en) 2010-12-09
JP2007505923A (ja) 2007-03-15
WO2005027844A3 (en) 2005-10-06
JP4989224B2 (ja) 2012-08-01
ES2399875T3 (es) 2013-04-04
EP1667523A2 (en) 2006-06-14
WO2005027844A2 (en) 2005-03-31
US8003113B2 (en) 2011-08-23
US20120207782A1 (en) 2012-08-16
PL1667523T3 (pl) 2013-05-31
CA2538840A1 (en) 2005-03-31
NZ545954A (en) 2009-04-30
IL174325A (en) 2015-07-30
US20050112102A1 (en) 2005-05-26
EP1667523A4 (en) 2007-12-19
CA2538840C (en) 2014-02-18
IL174325A0 (en) 2008-04-13
BRPI0414442A (pt) 2006-11-14
US7488485B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
FR23C1005I1 (fr) Vaccins contre les flavivirus
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1701968T3 (da) Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
DK1791852T3 (da) C-aryl glucosid -SGLT2-inhibitorer og metode til deres fremstilling
DK2578685T3 (da) Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
EP1678292A4 (en) IMPROVED MVA VACCINES
NO20025488L (no) Stabiliserte tetrasoliumreagenssammensetninger og fremgangsmater for deres anvendelse
DK1664343T3 (da) Fremgangsmåder og sammensætninger til generering af kimcelle humane antistofgener
NO20025489D0 (no) Stabiliserte tetrasolium-fenasin-reagens-sammensetninger og fremgangsmÕter for deres anvendelse
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
NO20050132D0 (no) Vaksinesammensetning
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
MA28609B1 (fr) Vaccins
DK1613346T3 (da) Mikrofluidiske olie-i-vand-emulsioner og vaccinesammensætninger
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
DK1730301T3 (da) Fremgangsmåder og sammensætninger til at analysere AHASL-gener
NO20053892D0 (no) Virale polymeraseinhibitorer
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
MA28885B1 (fr) vaccins
DK2308900T3 (da) Immunogene sammensætninger og fremgangsmåder til anvendelse
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
MA28639B1 (fr) Vaccins
IS7831A (is) Bóluefni
NO20054120D0 (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav